VERTEX PHARMACEUTICALS INC / MA VRTX

Vertex's CF franchise delivered strong double-digit growth in Q3 FY25, driven by ALYFTREK's ongoing launch in the U.S. and Europe, progress with younger patients and rare mutations, and expansion into new geographies like Brazil and Turkey. ALYFTREK, the fifth CFTR modulator, is seeing rapid uptake, especially among modulator-naive patients, and is expected to become the preferred treatment for most eligible patients globally due to its improved CFTR function, broader mutation coverage, and once-daily dosing. The pivotal study for TRIKAFTA in 1- to 2-year-olds showed remarkable sweat chloride reductions, with nearly 70% achieving normal levels, leading to global regulatory submissions planned for H1 2026. Additionally, the company initiated the CF cohort for VX-828, a NextGen 3.0 CFTR corrector, aiming to achieve normal sweat chloride levels in more patients.

CASGEVY, the one-time^📎 treatment for severe sickle cell disease and beta thalassemia, continues to build global momentum, with over $100 million in revenue projected for FY25 and significant growth in 2026. Reimbursement has been secured in Italy, a key market for TDT patients. Since launch, nearly 300 patients have been referred, over 160 have had their first cell collection (110 in the first 9 months of 2025 alone), and 39 patients have received infusions, including 10 in Q3 FY25. The company is seeing continued growth in authorized treatment centers (ATCs) onboarding and initiating patients across the U.S., Europe, and the Middle East, with 25 ATCs having initiated more than 5 patients.

The launch of JOURNAVX for moderate to severe acute pain is progressing well, with over 300,000 prescriptions filled as of mid-October. Payer coverage has expanded to over 170 million lives, with 113 million having unrestricted access. The company has formal coverage with two of the three large national PBMs and is in active discussions with the third. Hospital formulary adoption is strong, with over 750 hospitals and 90 large healthcare systems adding JOURNAVX. Physician adoption is broad across various specialties, and the company plans to add 150 sales representatives in Q1 2026 to increase prescriber engagement and expand coverage. Phase IV data showed approximately 90% of participants were opioid-free post-procedure, demonstrating significant opioid reduction.

Vertex is establishing itself as a leader in renal medicine with a broad pipeline. VX-407 for ADPKD initiated a Phase II proof-of-concept study, targeting the root cause of the disease. Inaxaplin for AMKD completed enrollment for the interim analysis cohort of the AMPLITUDE pivotal study, with potential for accelerated approval in the U.S. in H1 2026 if positive. The AMPLIFIED Phase II study for inaxaplin in AMKD with moderate proteinuria or diabetes is on track for enrollment completion by year-end. Povetacicept (pove) for IgAN completed full enrollment in the RAINIER Phase 3 trial, received FDA Breakthrough Therapy Designation and rolling review, and is set for BLA submission in H1 2026 with priority review. Pove also initiated a pivotal study for primary membranous nephropathy (pMN), with FDA Fast Track designation.

Vertex reported Q3 FY25 total revenue of $3.08 billion, an 11% year-over-year increase, with U.S. revenue growing 15%. Non-GAAP operating expenses rose 19% to $1.28 billion, driven by accelerated pove development and JOURNAVX commercialization. Non-GAAP EPS increased 10% to $4.80. The company ended the quarter with $12 billion in cash and investments and repurchased $1.1 billion of shares in Q3, totaling $1.9 billion year-to-date. Capital allocation priorities remain consistent: reinvestment in internal and external innovation, followed by share buybacks. The company is open to various deal types that align with its R&D strategy, focusing on high unmet need and validated targets.

Enrollment for the pivotal trial of Zimislecel in Type 1 Diabetes (T1D) has been completed, but dosing has been temporarily postponed due to an internal manufacturing analysis. The company emphasized maintaining study integrity and will provide updates once dosing is complete. For the DM1 program, the SAD portion has been completed, and the study is currently in the MAD portion. Results for the DM1 program, which evaluates safety and efficacy directly in patients, are expected next year.